Show simple item record

dc.contributor.authorD’Amico, Francesco
dc.contributor.authorFeliu-Soler, Albert
dc.contributor.authorMontero-Marín, Jesús
dc.contributor.authorPeñarrubía-María, María T.
dc.contributor.authorNavarro-Gil, Mayte
dc.contributor.authorVan Gordon, William
dc.contributor.authorGarcía-Campayo, Javier
dc.contributor.authorLuciano, Juan V.
dc.identifier.citationD’Amico, F., Feliu-Soler, A., Montero-Marín, J., Peñarrubía-María, M.T., Navarro-Gil, M., Van Gordon, W., García-Campayo, J. and Luciano, J.V., (2020). ‘Cost-utility of attachment-based compassion therapy (ABCT) for fibromyalgia compared to relaxation: a pilot randomized controlled trial’. Journal of Clinical Medicine, 9(3), pp. 1-14.en_US
dc.description.abstractA recent study has supported the efficacy of Attachment-Based Compassion Therapy (ABCT) compared to relaxation (REL) for the management of fibromyalgia (FM). The main objective of this paper is to examine the cost-utility of ABCT compared to REL in terms of effects on quality-adjusted life years (QALYs) as well as healthcare costs. Forty-two Spanish patients with FM received 8 weekly group sessions of ABCT or REL. Data collection took place at pre- and 3-month follow-up. Cost-utility of the two treatment groups (ABCT vs. REL) was compared by examining treatment outcomes in terms of QALYs (obtained with the EQ-5D-3L) and healthcare costs (data about service use obtained with the Client Service Receipt Inventory). Data analyses were computed from a completers, ITT, and per protocol approach. Data analysis from the healthcare perspective revealed that those patients receiving ABCT exhibited larger improvements in quality of life than those doing relaxation, while being less costly 3 months after their 8-week treatment program had ended (completers: incremental cost M, 95% CI = €−194.1 (−450.3 to 356.1); incremental effect M, 95% CI = 0.023 QALYs (0.010 to 0.141)). Results were similar using an ITT approach (incremental cost M, 95% CI = €−256.3 (−447.4 to −65.3); incremental effect M, 95% CI = 0.021 QALYs (0.009 to 0.033)). A similar pattern of results were obtained from the per protocol approach. This RCT has contributed to the evidence base of compassion-based interventions and provided useful information about the cost-utility of ABCT for FM patients when compared to relaxation. However, the small sample size and short follow-up period limited the generalizability of the findingsen_US
dc.description.sponsorshipThis research is financed by a grant from the ISCIII, Spanish Ministry Economy and Competitiveness (PI19/00805) and the Network for Prevention and Health Promotion in primary Care (ISCIII; RD16/0007/0005), co-financed with European Union ERDF funds.en_US
dc.publisherMDPI AGen_US
dc.rightsCC0 1.0 Universal*
dc.titleCost-utility of attachment-based compassion therapy (ABCT) for fibromyalgia compared to relaxation: a pilot randomized controlled trialen_US
dc.contributor.departmentLondon School of Economics and Political Scienceen_US
dc.contributor.departmentInstitut de Recerca Sant Joan de Déu, 08950 Esplugues de Llobregat, Spainen_US
dc.contributor.departmentParc Sanitari Sant Joan de Déu, 08830 St. Boi de Llobregat, Spainen_US
dc.contributor.departmentUniversity of Barcelonaen_US
dc.contributor.departmentUniversity of Oxforden_US
dc.contributor.departmentPHC Bartomeu Fabrés Anglada, DAP Baix Llobregat Litoral, Unitat Docent Costa de Ponent, Institut Català de la Salut, 08850 Gavà, Spainen_US
dc.contributor.departmentCentre for Biomedical Research in Epidemiology and Public Health, CIBERESP, 28029 Madrid, Spainen_US
dc.contributor.departmentMiguel Servet Hospital, Aragon Institute of Health Sciences (I+CS), 50009 Zaragoza, Spainen_US
dc.contributor.departmentPrimary Care Prevention and Health Promotion Research Network, RedIAPP, 28029 Madrid, Spainen_US
dc.identifier.journalJournal of Clinical Medicineen_US
dc.source.journaltitleJournal of Clinical Medicine

Files in this item

J Clin Med_Compassion Utility.pdf

This item appears in the following Collection(s)

Show simple item record

CC0 1.0 Universal
Except where otherwise noted, this item's license is described as CC0 1.0 Universal